Evolving Landscape of ADT in Prostate Cancer
EVENT DETAILS
ACCREDITATION
Moderator: Fred Saad
Speakers: Andrew Loblaw & Ricardo Rendon
OBJECTIVES
By participating in this learning program, healthcare providers can expect to:
- Describe the role of Androgen Deprivation Therapy (ADT) from a multidisciplinary perspective and apply advanced prostate cancer treatment strategies that take into consideration the risks and benefits of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists.
- Evaluate the benefits and limitations of available ADT options (luteinizing hormone–releasing hormone [LHRH] agonists, gonadotropin-releasing hormone [GnRH] agonists and antagonists) for patients with advanced prostate cancer according to clinical efficacy, CV risk, mechanism of action, route of administration and other practical considerations.
- Design and integrate an individualized treatment plan that includes the most appropriate ADT according to clinical considerations and patient preferences at various stages of the prostate cancer disease continuum, including:
- High risk localized disease
- Biochemical recurrence
- Newly diagnosed metastatic hormone sensitive
Simultaneous interpretation from English to French will be available